EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists

Jessalyn J Baljon, Alexander J Kwiatkowski, Hayden M Pagendarm iD, Payton T Stone, Amrendra Kumar, Vijaya Bharti, Jacob A Schulman, Kyle W Becker iD, Eric W Roth, Plamen P Christov, Sebastian Joyce, John T Wilson iD

ACS Nano · 05.03.2024 · 18 (9) · 6845-6862

DOI: 10.1021/acsnano.3c04471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 22.02.2024. Verfasst von Jessalyn J Baljon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 128-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIDCR NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsNanoparticlesHumansAnimalsMiceCD8-Positive T-LymphocytesToll-Like Receptor 4NanovaccinesAntigensPeptidesAdjuvants, ImmunologicImmunotherapyMice, Inbred C57BLTumor Microenvironment

Stichwörter der Autor:innen

adjuvant synergycancer vaccineendosomal escapeimmune checkpoint blockadeimmunotherapynanoparticle

Substanzen

Toll-Like Receptor 4NanovaccinesCancer VaccinesAntigensPeptidesAdjuvants, ImmunologicTLR4 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
  • Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Northwestern University Atomic and Nanoscale Characterization Experimental (NUANCE) Center, Northwestern University, Evanston, Illinois 60208, United States.
  • Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Department of Veteran Affairs Tennessee Valley Healthcare System, Nashville, Tennessee 37212, United States.

ORCID-Profile: Hayden M Pagendarm, Kyle W Becker, John T Wilson

Förderung

  • BLRD VA
  • NIDCR NIH HHS
  • NIDDK NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • Vanderbilt-Ingram Cancer Center
  • National Cancer Institute

Zitieren

APA

Baljon, J. J., Kwiatkowski, A. J., Pagendarm, H. M., Stone, P. T., Kumar, A., Bharti, V., Schulman, J. A., Becker, K. W., Roth, E. W., Christov, P. P., Joyce, S., & Wilson, J. T. (2024). A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. ACS Nano, 18(9), 6845-6862. https://doi.org/10.1021/acsnano.3c04471

Vancouver

Baljon JJ, Kwiatkowski AJ, Pagendarm HM, Stone PT, Kumar A, Bharti V, et al. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. ACS Nano. 2024;18(9):6845-6862. doi:10.1021/acsnano.3c04471

BibTeX
@article{Baljon2024,
  author = {Baljon, Jessalyn J and Kwiatkowski, Alexander J and Pagendarm, Hayden M and Stone, Payton T and Kumar, Amrendra and Bharti, Vijaya and Schulman, Jacob A and Becker, Kyle W and Roth, Eric W and Christov, Plamen P and Joyce, Sebastian and Wilson, John T},
  title = {A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {9},
  pages = {6845--6862},
  doi = {10.1021/acsnano.3c04471}
}
Kostenlos starten →